VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

September 14, 2011 15:08 ET

VentriPoint Announces Final Acceptance of Shares for Debt and Grant of Options

SEATTLE, WASHINGTON--(Marketwire - Sept. 14, 2011) -


VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Company") (TSX VENTURE:VPT) (PINK SHEETS:VPTDF) announces that, further to its previously issued press release of July 19, 2011, it has received final TSX Venture Exchange approval of the issuance of 155,463 common shares of the Company (the "Common Shares") at a deemed price of $0.16 per share in satisfaction of outstanding debt owed to a debentureholder and 190,000 Common Shares at a deemed price of $0.18 per share for payment of services rendered by non-officer directors and for outstanding debts owing to an arm's length third party. The deemed prices per share were based on the 10 day trading average as at July 19, 2011 of $0.20.

The Common Shares issued have a hold period of four months from the date of issuance in accordance with applicable securities legislation.

The Corporation also announces that it has granted 200,000 options to an officer of the Corporation. The options are exercisable at $0.24 per share until the fifth anniversary date of the grant.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Contact Information